Rajiv Nair, MD
Cardiovascular Disease · Bloomfield Hills, MINPI 1780609776
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $17,882 of the $28,117 with a category attached, or 63.6%. 24 manufacturers reported payments, led by Biotronik Inc. at 30.7% of the total.
Across 206 payments — averaging $136.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$9K
- Medtronic$6K
- Medical Device Business Services, Inc.$5K
- Boston Scientific$4K
- Abbott$2K
- Endologix LLC$973
- plus $1K from 18 others
Across 3 payments — averaging $2974.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$9K
What the payments were for
- Travel & lodging$17,88264%
- Food & beverage$10,14636%
- Education$160%
- Other$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 47 | $8,641 |
| Medtronic(2 entities) | 50 | $6,465 |
| Medical Device Business Services, Inc. | 18 | $4,513 |
| Boston Scientific | 18 | $3,950 |
| Abbott | 27 | $2,105 |
| Endologix LLC | 6 | $973 |
| Biosense Webster, Inc. | 15 | $664 |
| Cordis US CORP. | 1 | $249 |
| Baxter Healthcare | 3 | $105 |
| Johnson & Johnson | 6 | $81 |
| Ancora Heart, Inc. | 1 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Abiomed | 1 | $33 |
| Cleerly, Inc. | 1 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Pfizer | 1 | $25 |
| Cardiva Medical, Inc. | 1 | $24 |
| Terumo Medical Corporation | 1 | $24 |
| Elutia, Inc. | 1 | $21 |
| Cvrx, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Davol Inc. | 1 | $18 |
| Atricure, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$4,277
- Farapulse$3,592
- Micra$2,082
- BioMonitor$1,427
- Solia$1,427
- Acticor 7 VR-T DX$1,389
- AVEIR$997
- Edora 8 DR-T$837
- Rivacor 7 DR-T$837
- Selectra$697
- AMVIA EDGE$431
- ACCENT$257
- Arctic Front$219
- Rivacor$159
- Edora$159
- Acticor$159
- COBALT DR MRI SURESCAN$158
- AZURE XT DR MRI SURESCAN$149
- Cobalt$140
- Carto Smarttouch$123
How this compares
$28,117 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 706 | $910,166 |
| XareltoRivaroxaban | 162 | $205,397 |
| MultaqDronedarone Hcl | 42 | $64,996 |
| Flecainide Acetate | 216 | $11,182 |
| Dofetilide | 79 | $10,857 |
| Metoprolol Succinate | 423 | $9,360 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $7,884 |
| Propafenone Hcl | 105 | $7,114 |
| Quinidine Gluconate | 13 | $6,709 |
| Amiodarone Hcl | 150 | $4,090 |
| SotalolSotalol Hcl | 132 | $3,235 |
| Digoxin | 71 | $2,071 |
| Carvedilol | 98 | $1,235 |
| Warfarin Sodium | 44 | $935 |
| Sucralfate | 25 | $854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $910,166706 claims |
| Johnson & JohnsonXarelto | $81 | $205,397162 claims |
| Sanofi-aventis U.S. LLCMultaq | $35 | $64,99642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Bloomfield Hills
- Michele DegregorioBloomfield Hills$102K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.